Adams, S. C., DeLorey, D. S., Davenport, M. H., Fairey, A. S., North, S., & Courneya, K. S. (2018). Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors. Br J Cancer, 118(10), 1313-1321. https://doi.org/10.1038/s41416-018-0044-7
Adra, N., Abonour, R., Althouse, S. K., Albany, C., Hanna, N. H., & Einhorn, L. H. (2017). High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. J Clin Oncol, 35(10), 1096-1102. https://doi.org/10.1200/JCO.2016.69.5395
Adra, N., Albany, C., Sonneburg, D., Tong, Y., Hanna, N., & Einhorn, L. (2014). A retrospective analysis of patients with poor-risk germ cell tumor (PRGCT) treated at Indiana University from 2000 to 2010. J Clin Oncol, 31, (suppl; abstra 4557.
Adra, N., Althouse, S. K., Liu, H., Brames, M. J., Hanna, N. H., Einhorn, L. H., & Albany, C. (2016). Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014. Ann Oncol, 27(5), 875-879. https://doi.org/10.1093/annonc/mdw045
Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., . . . Hanna, N. H. (2018). Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol, 29(1), 209-214. https://doi.org/10.1093/annonc/mdx680
Al-Jebari, Y., Glimelius, I., Berglund Nord, C., Cohn-Cedermark, G., Stahl, O., Tandstad, T., . . . Giwercman, A. (2019). Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study. PLoS Med, 16(6), e1002816. https://doi.org/10.1371/journal.pmed.1002816
Albany, C., & Einhorn, L. H. (2013). Extragonadal germ cell tumors: clinical presentation and management. Curr Opin Oncol, 25(3), 261-265. https://doi.org/10.1097/CCO.0b013e32835f085d
Albany, C., Kesler, K., & Cary, C. (2019). Management of Residual Mass in Germ Cell Tumors After Chemotherapy. Curr Oncol Rep, 21(1), 5. https://doi.org/10.1007/s11912-019-0758-6
Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., . . . Laguna, M. P. (2011). EAU Guidelines on Testicular Cancer: 2011 Update. European Urology, 60(2), 304-319.
Albers, P., Bender, H., Yilmaz, H., Schoeneich, G., Biersack, H. J., & Mueller, S. C. (1999). Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology, 53(4), 808-811.
Albers, P., Goll, A., Bierhoff, E., Schoeneich, G., & Muller, S. C. (1999). Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. Urology, 54(4), 714-718.
Albers, P., Melchior, D., & Muller, S. C. (2003). Surgery in metastatic testicular cancer. Eur Urol, 44(2), 233-244. https://doi.org/10.1016/s0302-2838(03)00252-5
Albers, P., Siener, R., Krege, S., Schmelz, H.-U., Dieckmann, K.-P., Heidenreich, A., . . . Hartmann, M. (2008). Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol, JCO.2007.2012.0899. https://doi.org/10.1200/jco.2007.12.0899
Alexander, E. J., White, I. M., & Horwich, A. (2010). Update on management of seminoma. Indian J Urol, 26(1), 82-91. https://doi.org/10.4103/0970-1591.60451
Almstrup, K., Lobo, J., Morup, N., Belge, G., Rajpert-De Meyts, E., Looijenga, L. H. J., & Dieckmann, K. P. (2020). Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nat Rev Urol, 17(4), 201-213. https://doi.org/10.1038/s41585-020-0296-x
Andreassen, K. E., Grotmol, T., Cvancarova, M. S., Johannesen, T. B., & Fossa, S. D. (2011). Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007). Int J Cancer, 129(12), 2867-2874. https://doi.org/10.1002/ijc.25943
Aparicio, J., Germa, J. R., Garcia del Muro, X., Maroto, P., Arranz, J. A., Saenz, A., . . . Sanchez, A. (2005). Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol, 23(34), 8717-8723.
https://pubmed.ncbi.nlm.nih.gov/16260698/
10.1200/JCO.2005.01.9810
Aparicio, J., Maroto, P., del Muro, X. G., Guma, J., Sanchez-Munoz, A., Margeli, M., . . . Germa, J. R. (2011). Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol, 29(35), 4677-4681. https://doi.org/10.1200/JCO.2011.36.0503
Bachner, M., Loriot, Y., Gross-Goupil, M., Zucali, P. A., Horwich, A., Germa-Lluch, J. R., . . . De Santis, M. (2011). 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol.
https://pubmed.ncbi.nlm.nih.gov/21460378/
10.1093/annonc/mdr052
Balawender, K., Orkisz, S., & Wisz, P. (2018). Testicular microlithiasis: what urologists should know. A review of the current literature. Cent European J Urol, 71(3), 310-314. https://doi.org/10.5173/ceju.2018.1728
Bamberg, M., Schmidberger, H., Meisner, C., Classen, J., Souchon, R., Weinknecht, S., . . . Flink, M. (1999). Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer, 83(6), 823-827.
Bang, A. K., Petersen, J. H., Petersen, P. M., Andersson, A. M., Daugaard, G., & Jorgensen, N. (2009). Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. Int J Radiat Oncol Biol Phys, 75(3), 672-676. https://doi.org/10.1016/j.ijrobp.2008.11.057
Baniel, J., Foster, R. S., Gonin, R., Messemer, J. E., Donohue, J. P., & Einhorn, L. H. (1995). Late relapse of testicular cancer. J Clin Oncol, 13(5), 1170-1176.
Baniel, J., Foster, R. S., Rowland, R. G., Bihrle, R., & Donohue, J. P. (1994). Complications of primary retroperitoneal lymph node dissection. J Urol, 152(2 Pt 1), 424-427.
Beck, S. D., Peterson, M. D., Bihrle, R., Donohue, J. P., & Foster, R. S. (2007). Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patients. J Urol, 178(2), 504-506; discussion 506. https://doi.org/10.1016/j.juro.2007.03.123
Besse, B., Grunenwald, D., Flechon, A., Caty, A., Chevreau, C., Culine, S., . . . Fizazi, K. (2009). Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg, 137(2), 448-452. https://doi.org/10.1016/j.jtcvs.2008.09.032
Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., . . . Wittekind, C. (2013). Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol, 24(4), 878-888. https://doi.org/10.1093/annonc/mds579
Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., . . . Wittekind, C. (2012). Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Annals of Oncology.
Bezan, A., Posch, F., Ploner, F., Bauernhofer, T., Pichler, M., Szkandera, J., . . . Stotz, M. (2017). Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One, 12(4), e0176283. https://doi.org/10.1371/journal.pone.0176283
Bhala, N., Coleman, J. M., Radstone, C. R., Horsman, J. M., George, J., Hancock, B. W., . . . Coleman, R. E. (2004). The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients. Clin Oncol (R Coll Radiol), 16(1), 40-47. https://doi.org/10.1016/s0936-6555(03)00166-3
Bjerner, J., Biernat, D., Fossa, S. D., & Bjoro, T. (2009). Reference intervals for serum testosterone, SHBG, LH and FSH in males from the NORIP project. Scand J Clin Lab Invest, 69(8), 873-879 e871-811. https://doi.org/10.3109/00365510903380886
Bokemeyer, C., Hartmann, J. T., Fossa, S. D., Droz, J. P., Schmol, H. J., Horwich, A., . . . Einhorn, L. (2003). Extragonadal germ cell tumors: relation to testicular neoplasia and management options. APMIS, 111(1), 49-59; discussion 59-63. https://doi.org/10.1034/j.1600-0463.2003.11101081.x
Bokemeyer, C., Kollmannsberger, C., Stenning, S., Hartmann, J. T., Horwich, A., Clemm, C., . . . Oliver, T. (2004). Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer, 91(4), 683-687. https://doi.org/10.1038/sj.bjc.6602020
6602020 [pii]
Bokemeyer, C., Nichols, C. R., Droz, J. P., Schmoll, H. J., Horwich, A., Gerl, A., . . . Hartmann, J. T. (2002). Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol, 20(7), 1864-1873.
Bokemeyer, C., Oechsle, K., Honecker, F., Mayer, F., Hartmann, J. T., Waller, C. F., . . . Kollmannsberger, C. (2008). Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol, 19(3), 448-453.
https://pubmed.ncbi.nlm.nih.gov/18006893/
10.1093/annonc/mdm526
Bower, J. E., Bak, K., Berger, A., Breitbart, W., Escalante, C. P., Ganz, P. A., . . . American Society of Clinical, O. (2014). Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol, 32(17), 1840-1850. https://doi.org/10.1200/JCO.2013.53.4495
Brown, P. D., Pugh, S., Laack, N. N., Wefel, J. S., Khuntia, D., Meyers, C., . . . Radiation Therapy Oncology, G. (2013). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol, 15(10), 1429-1437. https://doi.org/10.1093/neuonc/not114
Brydoy, M., Fossa, S. D., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., & Dahl, O. (2005). Paternity following treatment for testicular cancer. J Natl Cancer Inst, 97(21), 1580-1588. https://doi.org/10.1093/jnci/dji339
Brydoy, M., Oldenburg, J., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., . . . Fossa, S. D. (2009). Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst, 101(24), 1682-1695. https://doi.org/10.1093/jnci/djp413
Busch, J., Seidel, C., & Zengerling, F. (2016). Male Extragonadal Germ Cell Tumors of the Adult. Oncol Res Treat, 39(3), 140-144. https://doi.org/10.1159/000444271
Calaway, A. C., Tachibana, I., Masterson, T. A., Foster, R. S., Einhorn, L. H., & Cary, C. (2019). Oncologic Outcomes Following Surgical Management of Clinical Stage II Sex Cord Stromal Tumors. Urology, 127, 74-79. https://doi.org/10.1016/j.urology.2019.02.014
Capelouto, C. C., Clark, P. E., Ransil, B. J., & Loughlin, K. R. (1995). A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol, 153(3 Pt 2), 981-985.
Carver, B. S., Cronin, A. M., Eggener, S., Savage, C. J., Motzer, R. J., Bajorin, D., . . . Sheinfeld, J. (2010). The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology, 75(6), 1431-1435. https://doi.org/10.1016/j.urology.2009.11.076
Cathomas, R., Klingbiel, D., Bernard, B., Lorch, A., Garcia Del Muro, X., Morelli, F., . . . Beyer, J. (2018). Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol, JCO1800210. https://doi.org/10.1200/JCO.18.00210
Cheney, S. M., Andrews, P. E., Leibovich, B. C., & Castle, E. P. (2015). Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. BJU Int, 115(1), 114-120. https://doi.org/10.1111/bju.12804
Cho, J. S., Kaimakliotis, H. Z., Cary, C., Masterson, T. A., Beck, S., & Foster, R. (2017). Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update. BJU Int, 120(1), 104-108. https://doi.org/10.1111/bju.13844
Christensen, T. B., Engbaek, F., Marqversen, J., Nielsen, S. I., Kamby, C., & von der Maase, H. (1999). 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. Br J Cancer, 80(10), 1577-1581. https://doi.org/10.1038/sj.bjc.6690565
Christian, J. A., Huddart, R. A., Norman, A., Mason, M., Fossa, S., Aass, N., . . . Horwich, A. (2003). Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol, 21(5), 871-877. https://doi.org/10.1200/JCO.2003.05.155
Chung, P. W., Daugaard, G., Tyldesley, S., Panzarella, T., Kollmannsberger, C. K., Gospodarowicz, M., & Warde, P. (2010). Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. J Clin Oncol, 28(7s), suppl; abstr 4535.
Chung, P. W., Gospodarowicz, M. K., Panzarella, T., Jewett, M. A., Sturgeon, J. F., Tew-George, B., . . . Warde, P. R. (2004). Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol, 45(6), 754-759; discussion 759-760. https://doi.org/10.1016/j.eururo.2004.01.020
Classen, J., Schmidberger, H., Meisner, C., Souchon, R., Sautter-Bihl, M. L., Sauer, R., . . . Bamberg, M. (2003). Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol, 21(6), 1101-1106.
Coogan, C. L., Foster, R. S., Simmons, G. R., Tognoni, P. G., Roth, B. J., & Donohue, J. P. (1998). Bilateral testicular tumors: management and outcome in 21 patients. Cancer, 83(3), 547-552.
Crona, D. J., Faso, A., Nishijima, T. F., McGraw, K. A., Galsky, M. D., & Milowsky, M. I. (2017). A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist, 22(5), 609-619. https://doi.org/10.1634/theoncologist.2016-0319
Culine, S., Kramar, A., Theodore, C., Geoffrois, L., Chevreau, C., Biron, P., . . . Genito-Urinary Group of the French Federation of Cancer Centers Trial, T. M. (2008). Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol, 26(3), 421-427. https://doi.org/10.1200/JCO.2007.13.8461
Daneshmand, S., Albers, P., Fossa, S. D., Heidenreich, A., Kollmannsberger, C., Krege, S., . . . Wood, L. (2012). Contemporary management of postchemotherapy testis cancer. Eur Urol, 62(5), 867-876. https://doi.org/10.1016/j.eururo.2012.08.014
Daugaard, G., Petersen, P. M., & Rorth, M. (2003). Surveillance in stage I testicular cancer. APMIS, 111(1), 76-83; discussion 83-75. https://doi.org/10.1034/j.1600-0463.2003.11101111.x
Daugaard, G., Skoneczna, I., Aass, N., De Wit, R., De Santis, M., Dumez, H., . . . Schmoll, H. J. (2010). A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol.
https://pubmed.ncbi.nlm.nih.gov/21059637/
10.1093/annonc/mdq575
De Giorgi, U., Rosti, G., Aieta, M., Testore, F., Burattini, L., Fornarini, G., . . . Marangolo, M. (2006). Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol, 50(5), 1032-1038; discussion 1038-1039.
https://pubmed.ncbi.nlm.nih.gov/16757095/
10.1016/j.eururo.2006.05.011
De Giorgi, U., Rosti, G., Papiani, G., Aieta, M., Fochessati, F., Paoluzzi, L., . . . Marangolo, M. (2004). Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience. Am J Clin Oncol, 27(5), 457-460.
https://pubmed.ncbi.nlm.nih.gov/15596910/
De Santis, M., Becherer, A., Bokemeyer, C., Stoiber, F., Oechsle, K., Sellner, F., . . . Pont, J. (2004). 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol, 22(6), 1034-1039. https://doi.org/10.1200/JCO.2004.07.188
JCO.2004.07.188 [pii]
de Wit, M., Brenner, W., Hartmann, M., Kotzerke, J., Hellwig, D., Lehmann, J., . . . Bares, R. (2008). [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol, 19(9), 1619-1623. https://doi.org/10.1093/annonc/mdn170
de Wit, R., Roberts, J. T., Wilkinson, P. M., de Mulder, P. H., Mead, G. M., Fossa, S. D., . . . Collette, L. (2001). Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol, 19(6), 1629-1640.
de Wit, R., Skoneczna, I., Daugaard, G., De Santis, M., Garin, A., Aass, N., . . . Collette, L. (2012). Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol, 30(8), 792-799. https://doi.org/10.1200/JCO.2011.37.0171
de Wit, R., Sleijfer, S., Kaye, S. B., Horwich, A., Mead, B., Sleijfer, D. T., & Stoter, G. (2007). Bleomycin and scuba diving: where is the harm? Lancet Oncol, 8(11), 954-955. https://doi.org/10.1016/S1470-2045(07)70321-2
Del Risco Kollerud, R., Blaasaas, K. G., Claussen, B., Nafstad, P., Cannon-Albright, L. A., Ruud, E., . . . Naess, O. (2018). Family history of cancer and the risk of childhood solid tumours: a Norwegian nationwide register-based cohort study. Br J Cancer, 118(6), 905-912. https://doi.org/10.1038/bjc.2017.493
DeSantis, M., Albrecht, W., Holtl, W., & Pont, J. (1999). Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer, 83(6), 864-865.
Di Tonno, F., Tavolini, I. M., Belmonte, P., Bertoldin, R., Cossaro, E., Curti, P., . . . North-Eastern Uro-Oncological Group, I. (2009). Lessons from 52 patients with leydig cell tumor of the testis: the GUONE (North-Eastern Uro-Oncological Group, Italy) experience. Urologia Internationalis, 82(2), 152-157. https://doi.org/10.1159/000200790
Dieckmann, K. P., Albers, P., Classen, J., De Wit, M., Pichlmeier, U., Rick, O., . . . Kuczyk, M. (2005). Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol, 173(3), 824-829.https://pubmed.ncbi.nlm.nih.gov/15711278/
10.1097/01.ju.0000154013.96349.36
Dieckmann, K. P., Anheuser, P., Schmidt, S., Soyka-Hundt, B., Pichlmeier, U., Schriefer, P., . . . Ruf, C. G. (2015). Testicular prostheses in patients with testicular cancer - acceptance rate and patient satisfaction. BMC Urol, 15, 16. https://doi.org/10.1186/s12894-015-0010-0
Dieckmann, K. P., Bertolini, J., & Wulfing, C. (2019). Adult Granulosa Cell Tumor of the Testis: A Case Report with a Review of the Literature. Case Rep Urol, 2019, 7156154. https://doi.org/10.1155/2019/7156154
Dieckmann, K. P., Heinemann, V., Frey, U., Pichlmeier, U., & German Testicular Cancer Study, G. (2005). How harmful is contralateral testicular biopsy?--an analysis of serial imaging studies and a prospective evaluation of surgical complications. Eur Urol, 48(4), 662-672. https://doi.org/10.1016/j.eururo.2005.06.008
Dieckmann, K. P., Kulejewski, M., Pichlmeier, U., & Loy, V. (2007). Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol, 51(1), 175-183; discussion 183-175.
https://pubmed.ncbi.nlm.nih.gov/16814456/
10.1016/j.eururo.2006.05.051
Domont, J., Massard, C., Patrikidou, A., Bossi, A., de Crevoisier, R., Rose, M., . . . Fizazi, K. (2013). A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol, 31(5), 697-705. https://doi.org/10.1016/j.urolonc.2011.04.004
Donat, S. M., & Levy, D. A. (1998). Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol, 160(4), 1347-1352.
Donohue, J. P., & Foster, R. S. (1998). Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am, 25(3), 461-468. https://doi.org/10.1016/s0094-0143(05)70035-5
Doyle, D. M., & Einhorn, L. H. (2008). Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys, 70(5), 1361-1364. https://doi.org/10.1016/j.ijrobp.2007.11.005
Droz, J. P., Kramar, A., Biron, P., Pico, J. L., Kerbrat, P., Peny, J., . . . Culine, S. (2007). Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol, 51(3), 739-746; discussion 747-738.
https://pubmed.ncbi.nlm.nih.gov/17084512/
10.1016/j.eururo.2006.10.035
Eastham, J. A., Wilson, T. G., Russell, C., Ahlering, T. E., & Skinner, D. G. (1994). Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology, 43(1), 74-80. https://doi.org/10.1016/s0090-4295(94)80269-6
Eberhard, J., Stahl, O., Giwercman, Y., Cwikiel, M., Cavallin-Stahl, E., Lundin, K. B., . . . Giwercman, A. (2004). Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study. Hum. Reprod., 19(6), 1418-1425. https://doi.org/10.1093/humrep/deh231
Ehrlich, Y., Beck, S. D., Foster, R. S., Bihrle, R., & Einhorn, L. H. (2013). Serum tumor markers in testicular cancer. Urol Oncol, 31(1), 17-23. https://doi.org/10.1016/j.urolonc.2010.04.007
Ehrlich, Y., Brames, M. J., Beck, S. D., Foster, R. S., & Einhorn, L. H. (2010). Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol, 28(4), 531-536. https://doi.org/10.1200/JCO.2009.23.0714
Einhorn, L. H., Brames, M. J., Juliar, B., & Williams, S. D. (2007). Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol, 25(5), 513-516.
https://pubmed.ncbi.nlm.nih.gov/17290059/
10.1200/JCO.2006.07.7271
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007). High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med, 357(4), 340-348.
https://pubmed.ncbi.nlm.nih.gov/17652649/
10.1056/NEJMoa067749
Fankhauser, C. D., Grogg, J. B., Hayoz, S., Wettstein, M. S., Dieckmann, K. P., Sulser, T., . . . Hermanns, T. (2019). Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. J Urol, 101097JU0000000000000705. https://doi.org/10.1097/JU.0000000000000705
Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., . . . Cancer advisory, p. (2019). 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol, 20(10), e566-e581. https://doi.org/10.1016/S1470-2045(19)30336-5
Feldman, D. R., Lorch, A., Kramar, A., Albany, C., Einhorn, L. H., Giannatempo, P., . . . Powles, T. (2016). Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol, 34(4), 345-351. https://doi.org/10.1200/JCO.2015.62.7000
Feldman, D. R., Sheinfeld, J., Bajorin, D. F., Fischer, P., Turkula, S., Ishill, N., . . . Motzer, R. J. (2010). TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol, 28(10), 1706-1713. https://doi.org/10.1200/JCO.2009.25.1561
Fizazi, K., Delva, R., Caty, A., Chevreau, C., Kerbrat, P., Rolland, F., . . . Laplanche, A. (2014). A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. Eur Urol, 65(2), 381-386. https://doi.org/10.1016/j.eururo.2013.09.004
Fizazi, K., Oldenburg, J., Dunant, A., Chen, I., Salvioni, R., Hartmann, J. T., . . . Fromont, G. (2008). Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Annals of Oncology, 19(2), 259-264.
https://pubmed.ncbi.nlm.nih.gov/20550599/
Fizazi, K., Pagliaro, L., Laplanche, A., Flechon, A., Mardiak, J., Geoffrois, L., . . . Culine, S. (2014). Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol, 15(13), 1442-1450. https://doi.org/10.1016/S1470-2045(14)70490-5
Fizazi, K., Prow, D. M., Do, K. A., Wang, X., Finn, L., Kim, J., . . . Amato, R. J. (2002). Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer, 86(10), 1555-1560. https://doi.org/10.1038/sj.bjc.6600272
Fizazi, K., Tjulandin, S., Salvioni, R., Germa-Lluch, J. R., Bouzy, J., Ragan, D., . . . Mahe, C. (2001). Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol, 19(10), 2647-2657. https://doi.org/10.1200/JCO.2001.19.10.2647
Flechon, A., Bompas, E., Biron, P., & Droz, J. P. (2002). Management of post-chemotherapy residual masses in advanced seminoma. J Urol, 168(5), 1975-1979.
https://pubmed.ncbi.nlm.nih.gov/12394688/
Forsberg, L., Dale, L., Hoiem, L., Magnusson, A., Mikulowski, P., Olsson, A. M., . . . Stenwig, A. E. (1986). Computed tomography in early stages of testicular carcinoma. Size of normal retroperitoneal lymph nodes and lymph nodes in patients with metastases in stage II A. A SWENOTECA study: Swedish-Norwegian Testicular Cancer Project. Acta Radiol Diagn (Stockh), 27(5), 569-574. https://doi.org/10.1177/028418518602700516
Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). FOR-2000-12-01-1208. nr. 1208.
Fossa, S. D., Bokemeyer, C., Gerl, A., Culine, S., Jones, W. G., Mead, G. M., . . . Tjulandin, S. (1999). Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer, 85(4), 988-997.
https://pubmed.ncbi.nlm.nih.gov/10091779/
Fossa, S. D., Gilbert, E., Dores, G. M., Chen, J., McGlynn, K. A., Schonfeld, S., . . . Travis, L. B. (2007). Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst, 99(7), 533-544.
https://pubmed.ncbi.nlm.nih.gov/17405998/
10.1093/jnci/djk111
Fossa, S. D., Kaye, S. B., Mead, G. M., Cullen, M., de Wit, R., Bodrogi, I., . . . Collette, L. (1998). Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol, 16(2), 716-724. https://doi.org/10.1200/JCO.1998.16.2.716
Fossa, S. D., Ous, S., Lien, H. H., & Stenwig, A. E. (1989). Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol, 141(3), 557-559. https://doi.org/10.1016/s0022-5347(17)40892-5
Fossa, S. D., Paluchowska, B., Horwich, A., Kaiser, G., de Mulder, P. H., Koriakine, O., . . . Group, E. G. (2005). Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer, 93(11), 1209-1214. https://doi.org/10.1038/sj.bjc.6602830
Fossa, S. D., Stenning, S. P., Gerl, A., Horwich, A., Clark, P. I., Wilkinson, P. M., . . . Cook, P. A. (1999). Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer, 80(9), 1392-1399. https://doi.org/10.1038/sj.bjc.6690534
Fossa, S. D., Aass, N., Harvei, S., & Tretli, S. (2004). Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer, 90(3), 607-612. https://doi.org/10.1038/sj.bjc.6601558
Fossa, S. D., Aass, N., Winderen, M., Bormer, O. P., & Olsen, D. R. (2002). Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol, 13(2), 222-228.
Foster, R. S., Baniel, J., Leibovitch, I., Curran, M., Bihrle, R., Rowland, R., & Donohue, J. P. (1996). Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. J Urol, 155(6), 1943-1945.
Fox, E. P., Weathers, T. D., Williams, S. D., Loehrer, P. J., Ulbright, T. M., Donohue, J. P., & Einhorn, L. H. (1993). Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol, 11(7), 1294-1299. https://doi.org/10.1200/JCO.1993.11.7.1294
Frisina, R. D., Wheeler, H. E., Fossa, S. D., Kerns, S. L., Fung, C., Sesso, H. D., . . . Travis, L. B. (2016). Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol, 34(23), 2712-2720. https://doi.org/10.1200/JCO.2016.66.8822
Fung, C., Fossa, S. D., Milano, M. T., Oldenburg, J., & Travis, L. B. (2013). Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol, 31(30), 3807-3814. https://doi.org/10.1200/JCO.2013.50.3409
Gennaro, N., Sconfienza, L. M., Ambrogi, F., Boveri, S., & Lanza, E. (2019). Thermal ablation to relieve pain from metastatic bone disease: a systematic review. Skeletal Radiol, 48(8), 1161-1169. https://doi.org/10.1007/s00256-018-3140-0
George, D. W., Foster, R. S., Hromas, R. A., Robertson, K. A., Vance, G. H., Ulbright, T. M., . . . Einhorn, L. H. (2003). Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol, 21(1), 113-122. https://doi.org/10.1200/JCO.2003.03.019
Gerdtsson, A., Hakansson, U., Tornblom, M., Jancke, G., Negaard, H. F. S., Glimelius, I., . . . Kjellman, A. (2019). Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2019.08.002
Gerl, A., Clemm, C., Schmeller, N., Hentrich, M., Lamerz, R., & Wilmanns, W. (1997). Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol, 8(1), 41-47. https://doi.org/10.1023/a:1008253323854
Germa-Lluch, J. R., Garcia del Muro, X., Tabernero, J. M., Sanchez, M., Aparicio, J., Alba, E., & Barnadas, A. (1999). BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann Oncol, 10(3), 289-293. https://doi.org/10.1023/a:1008351022211
Ghezzi, M., Berretta, M., Bottacin, A., Palego, P., Sartini, B., Cosci, I., . . . Garolla, A. (2016). Impact of Bep or Carboplatin Chemotherapy on Testicular Function and Sperm Nucleus of Subjects with Testicular Germ Cell Tumor. Front Pharmacol, 7, 122. https://doi.org/10.3389/fphar.2016.00122
Ghodoussipour, S., & Daneshmand, S. (2020). Surgical strategies for postchemotherapy testis cancer. Transl Androl Urol, 9(Suppl 1), S74-S82. https://doi.org/10.21037/tau.2019.09.43
Giannatempo, P., Pond, G. R., Sonpavde, G., Albany, C., Loriot, Y., Sweeney, C. J., . . . Cary, C. (2016). Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. J Urol, 196(1), 95-100. https://doi.org/10.1016/j.juro.2015.12.082
Gizzi, M., Oberic, L., Massard, C., Poterie, A., Le Teuff, G., Loriot, Y., . . . Fizazi, K. (2016). Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer, 69, 151-157. https://doi.org/10.1016/j.ejca.2016.10.003
Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., . . . American Society of Clinical, O. (2012). Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 30(13), 1553-1561. https://doi.org/10.1200/JCO.2011.39.9436
Grogg, J., Schneider, K., Bode, P. K., Kranzbuhler, B., Eberli, D., Sulser, T., . . . Fankhauser, C. D. (2020). Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. Oncologist. https://doi.org/10.1634/theoncologist.2019-0692
Groot, H. J., Lubberts, S., de Wit, R., Witjes, J. A., Kerst, J. M., de Jong, I. J., . . . Schaapveld, M. (2018). Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. J Clin Oncol, 36(24), 2504-2513. https://doi.org/10.1200/JCO.2017.77.4174
Gupta, S. K., Lindemulder, E. A., & Sathyan, G. (2000). Modeling of circadian testosterone in healthy men and hypogonadal men. J Clin Pharmacol, 40(7), 731-738. https://doi.org/10.1177/00912700022009486
Hale, G. R., Teplitsky, S., Truong, H., Gold, S. A., Bloom, J. B., & Agarwal, P. K. (2018). Lymph node imaging in testicular cancer. Transl Androl Urol, 7(5), 864-874. https://doi.org/10.21037/tau.2018.07.18
Hall, E. J., & Wuu, C. S. (2003). Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys, 56(1), 83-88.
Hamid, A. A., Markt, S. C., Vicier, C., McDermott, K., Richardson, P., Ho, V. T., & Sweeney, C. J. (2019). Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clin Genitourin Cancer, 17(1), 58-64 e51. https://doi.org/10.1016/j.clgc.2018.09.009
Handbook for reporting results of cancer treatment. (1979). Geneva, Switzerland
Harland, S. J., Cook, P. A., Fossa, S. D., Horwich, A., Mead, G. M., Parkinson, M. C., . . . Stenning, S. P. (1998). Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol, 160(4), 1353-1357.
Hartmann, J. T., Candelaria, M., Kuczyk, M. A., Schmoll, H. J., & Bokemeyer, C. (1997). Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer, 33(6), 843-847.
Hartmann, J. T., Fossa, S. D., Nichols, C. R., Droz, J. P., Horwich, A., Gerl, A., . . . Bokemeyer, C. (2001). Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst, 93(22), 1733-1738. https://doi.org/10.1093/jnci/93.22.1733
Hartmann, J. T., Gauler, T., Metzner, B., Gerl, A., Casper, J., Rick, O., . . . German Testicular Cancer Study, G. (2007). Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol, 25(36), 5742-5747. https://doi.org/10.1200/JCO.2007.11.9099
Hartmann, J. T., & Lipp, H. P. (2006). Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf, 29(3), 209-230. https://doi.org/10.2165/00002018-200629030-00005
Hartmann, J. T., Nichols, C. R., Droz, J. P., Horwich, A., Gerl, A., Fossa, S. D., . . . Bokemeyer, C. (2000). Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst, 92(1), 54-61.
Hashimoto, K., Fujimoto, H., Kouno, T., Koseki, M., Yonemori, K., Hirata, T., . . . Fujiwara, Y. (2012). The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors. Urol Oncol, 30(3), 319-324. https://doi.org/10.1016/j.urolonc.2010.02.008
Haugnes, H. S., Laurell, A., Stierner, U., Bremnes, R. M., Dahl, O., Cavallin-Stahl, E., & Cohn-Cedermark, G. (2012). High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncol, 51(2), 168-176. https://doi.org/10.3109/0284186X.2011.641507
Haugnes, H. S., Oldenburg, J., & Bremnes, R. M. (2015). Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol Oncol, 33(9), 399-406. https://doi.org/10.1016/j.urolonc.2014.11.012
Haugnes, H. S., Stenklev, N. C., Brydoy, M., Dahl, O., Wilsgaard, T., Laukli, E., & Fossa, S. D. (2018). Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncol, 57(8), 1075-1083. https://doi.org/10.1080/0284186X.2018.1433323
Haugnes, H. S., Wethal, T., Aass, N., Dahl, O., Klepp, O., Langberg, C. W., . . . Fossa, S. D. (2010). Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol, 28(30), 4649-4657.
https://pubmed.ncbi.nlm.nih.gov/20855830/
10.1200/JCO.2010.29.9362
Haugnes, H. S., Aass, N., Fossa, S. D., Dahl, O., Brydoy, M., Aasebo, U., . . . Bremnes, R. M. (2009). Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol, 27(17), 2779-2786. https://doi.org/10.1200/JCO.2008.18.5181
Haugnes, H. S., Aass, N., Fossa, S. D., Dahl, O., Klepp, O., Wist, E. A., . . . Bremnes, R. M. (2007). Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol, 18(2), 241-248.
https://pubmed.ncbi.nlm.nih.gov/17060482/
10.1093/annonc/mdl372
Heidenreich, A., Albers, P., Hartmann, M., Kliesch, S., Kohrmann, K. U., Krege, S., . . . German Testicular Cancer Study, G. (2003). Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol, 169(5), 1710-1714. https://doi.org/10.1097/01.ju.0000060960.18092.54
Heidenreich, A., Paffenholz, P., Nestler, T., & Pfister, D. (2018). Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer. Oncol Res Treat, 41(6), 370-378. https://doi.org/10.1159/000489508
Heidenreich, A., Paffenholz, P., Nestler, T., Pfister, D., & Daneshmand, S. (2020). Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors. Curr Opin Urol, 30(2), 251-257. https://doi.org/10.1097/MOU.0000000000000736
Heidenreich, A., Pfister, D., Witthuhn, R., Thuer, D., & Albers, P. (2009). Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol, 55(1), 217-224. https://doi.org/10.1016/j.eururo.2008.09.027
Hellesnes, R., Kvammen, O., Myklebust, T. A., Bremnes, R. M., Karlsdottir, A., Negaard, H. F. S., . . . Haugnes, H. S. (2019). Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. Int J Cancer. https://doi.org/10.1002/ijc.32704
Herr, H. W., Sheinfeld, J., Puc, H. S., Heelan, R., Bajorin, D. F., Mencel, P., . . . Motzer, R. J. (1997a). Surgery for a post-chemotherapy residual mass in seminoma. J Urol, 157(3), 860-862.
Herr, H. W., Sheinfeld, J., Puc, H. S., Heelan, R., Bajorin, D. F., Mencel, P., . . . Motzer, R. J. (1997b). Surgery for a post-chemotherapy residual mass in seminoma. J Urol, 157(3), 860-862.
https://pubmed.ncbi.nlm.nih.gov/9072586/
Hiester, A., Nini, A., Fingerhut, A., Grosse Siemer, R., Winter, C., Albers, P., & Lusch, A. (2018). Preservation of Ejaculatory Function After Postchemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) in Patients With Testicular Cancer: Template vs. Bilateral Resection. Front Surg, 5, 80. https://doi.org/10.3389/fsurg.2018.00080
Hinton, S., Catalano, P. J., Einhorn, L. H., Nichols, C. R., David Crawford, E., Vogelzang, N., . . . Loehrer, P. J., Sr. (2003). Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer, 97(8), 1869-1875. https://doi.org/10.1002/cncr.11271
Hinze, A. M., & Wigley, F. M. (2018). Pharmacotherapy Options in the Management of Raynaud's Phenomenon. Curr Treatm Opt Rheumatol, 4(3), 235-254. https://doi.org/10.1007/s40674-018-0102-6
Hoenemeyer, T. W., Kaptchuk, T. J., Mehta, T. S., & Fontaine, K. R. (2018). Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial. Sci Rep, 8(1), 2784. https://doi.org/10.1038/s41598-018-20993-y
Hofmockel, G., Gruss, A., & Theiss, M. (1996). Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urologia Internationalis, 57(1), 38-42. https://doi.org/10.1159/000282874
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., . . . Horwich, A. (2018). ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol, 29(8), 1658-1686. https://doi.org/10.1093/annonc/mdy217
Horwich, A., Fossa, S. D., Stenning, S., Bliss, J., & Hall, E. J. (2010). Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. J Clin Oncol, 28(7s), suppl; abstr 4538.
Horwich, A., Oliver, R. T., Wilkinson, P. M., Mead, G. M., Harland, S. J., Cullen, M. H., . . . Stenning, S. P. (2000). A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer, 83(12), 1623-1629. https://doi.org/10.1054/bjoc.2000.1498
S0007092000914988 [pii]
Houck, W., Abonour, R., Vance, G., & Einhorn, L. H. (2004). Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J Clin Oncol, 22(11), 2155-2158. https://doi.org/10.1200/JCO.2004.11.054
Hu, B., & Daneshmand, S. (2018). Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma. Adv Urol, 2018, 7978958. https://doi.org/10.1155/2018/7978958
Hu, B., Shah, S., Shojaei, S., & Daneshmand, S. (2015). Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive Seminoma. Clin Genitourin Cancer, 13(4), e265-e269. https://doi.org/10.1016/j.clgc.2015.01.002
Hu, R., Ulbright, T. M., & Young, R. H. (2019). Spermatocytic Seminoma: A Report of 85 Cases Emphasizing Its Morphologic Spectrum Including Some Aspects Not Widely Known. Am J Surg Pathol, 43(1), 1-11. https://doi.org/10.1097/PAS.0000000000001001
Huddart, R. A., Gabe, R., Cafferty, F. H., Pollock, P., White, J. D., Shamash, J., . . . National Cancer Research Institute Testis Cancer Clinical Studies, G. (2015). A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Eur Urol, 67(3), 534-543. https://doi.org/10.1016/j.eururo.2014.06.034
Huddart, R. A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., & Dearnaley, D. P. (2003). Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol, 21(8), 1513-1523. https://doi.org/10.1200/JCO.2003.04.173
JCO.2003.04.173 [pii]
Huddart, R. A., O'Doherty, M. J., Padhani, A., Rustin, G. J., Mead, G. M., Joffe, J. K., . . . Group, N. T. T. C. S. (2007). 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol, 25(21), 3090-3095. https://doi.org/10.1200/JCO.2006.09.3831
ICRU, I. C. o. R. U. a. M. (1993). Prescribing, recording and reporting photon beam therapy report 50. Oxford University Press, Oxford, United Kingdom.
ICRU, I. C. o. R. U. a. M. (2010). Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU Report 83. J ICRU.
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. (1997). J Clin Oncol, 15(2), 594-603.
Iwamoto, H., Izumi, K., Natsagdorj, A., Makino, T., Nohara, T., Shigehara, K., . . . Mizokami, A. (2018). Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor. In Vivo, 32(4), 899-903. https://doi.org/10.21873/invivo.11326
Jacobsen, K. D., Ous, S., Waehre, H., Trasti, H., Stenwig, A. E., Lien, H. H., . . . Fossa, S. D. (1999). Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer, 80(1-2), 249-255. https://doi.org/10.1038/sj.bjc.6690347
Jacus, M. O., Daryani, V. M., Harstead, K. E., Patel, Y. T., Throm, S. L., & Stewart, C. F. (2016). Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet, 55(3), 297-311. https://doi.org/10.1007/s40262-015-0319-6
Joel, S. P., Shah, R., Clark, P. I., & Slevin, M. L. (1996). Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol, 14(1), 257-267. https://doi.org/10.1200/JCO.1996.14.1.257
Jordan, B., Margulies, A., Cardoso, F., Cavaletti, G., Haugnes, H. S., Jahn, P., . . . office@eano.eu, E. G. C. E. a. (2020). Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol, 31(10), 1306-1319. https://doi.org/10.1016/j.annonc.2020.07.003
Kamischke, A., & Nieschlag, E. (2002). Update on medical treatment of ejaculatory disorders. Int J Androl, 25(6), 333-344. https://doi.org/10.1046/j.1365-2605.2002.00379.x
Kesler, K. A., Rieger, K. M., Hammoud, Z. T., Kruter, L. E., Perkins, S. M., Turrentine, M. W., . . . Brown, J. W. (2008). A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg, 85(2), 371-378. https://doi.org/10.1016/j.athoracsur.2007.09.020
Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., . . . Falanga, A. (2020). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 38(5), 496-520. https://doi.org/10.1200/JCO.19.01461
Khetpal, R., Katz, M. D., Cox, M., & Arnaoutakis, K. (2014). The role of salvage hemiscrotectomy in testicular cancer after scrotal contamination: a case report and literature review. Clin Genitourin Cancer, 12(3), e103-105. https://doi.org/10.1016/j.clgc.2013.12.004
Kier, M. G., Hansen, M. K., Lauritsen, J., Mortensen, M. S., Bandak, M., Agerbaek, M., . . . Daugaard, G. (2016). Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study. JAMA Oncol, 2(12), 1624-1627. https://doi.org/10.1001/jamaoncol.2016.3651
Kleinschmidt, K., Dieckmann, K. P., Georgiew, A., Loy, V., & Weissbach, L. (2009). Chemotherapy is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer. Oncology, 77(1), 33-39. https://doi.org/10.1159/000218202
Klepp, O., Olsson, A. M., Ous, S., Nilsson, S., Hoisaether, P. A., & Tveter, K. (1991). Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project. Scand J Urol Nephrol, 25(3), 179-190.
Kliesch, S., Thomaidis, T., Schutte, B., Puhse, G., Kater, B., Roth, S., & Bergmann, M. (2003). Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN). APMIS, 111(1), 70-74; discussion 75.
Kollmannsberger, C., Beyer, J., Liersch, R., Schoeffski, P., Metzner, B., Hartmann, J. T., . . . Bokemeyer, C. (2004). Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol, 22(1), 108-114. https://doi.org/10.1200/JCO.2004.06.068
22/1/108 [pii]
Kollmannsberger, C., Daneshmand, S., So, A., Chi, K. N., Murray, N., Moore, C., . . . Nichols, C. (2010). Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol, 28(4), 537-542.
https://pubmed.ncbi.nlm.nih.gov/20026807/
10.1200/JCO.2009.23.0755
Kollmannsberger, C., Moore, C., Chi, K. N., Murray, N., Daneshmand, S., Gleave, M., . . . Nichols, C. R. (2010). Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol, 21(6), 1296-1301. https://doi.org/10.1093/annonc/mdp473
Kollmannsberger, C., Nichols, C., Meisner, C., Mayer, F., Kanz, L., & Bokemeyer, C. (2000). Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol, 11(9), 1115-1120. https://doi.org/10.1023/a:1008333229936
Kollmannsberger, C., Tandstad, T., Bedard, P. L., Cohn-Cedermark, G., Chung, P. W., Jewett, M. A., . . . Nichols, C. R. (2015). Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol, 33(1), 51-57. https://doi.org/10.1200/JCO.2014.56.2116
Kollmannsberger, C., Tyldesley, S., Moore, C., Chi, K. N., Murray, N., Daneshmand, S., . . . Nichols, C. (2010). Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol.
https://pubmed.ncbi.nlm.nih.gov/20926549/
10.1093/annonc/mdq466
Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., . . . Motzer, R. J. (2005). Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol, 23(27), 6549-6555.
https://pubmed.ncbi.nlm.nih.gov/16170162/
10.1200/JCO.2005.19.638
Kvammen, O., Myklebust, T. A., Solberg, A., Moller, B., Klepp, O. H., Fossa, S. D., & Tandstad, T. (2016). Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor. Cancer Epidemiol Biomarkers Prev, 25(5), 773-779. https://doi.org/10.1158/1055-9965.EPI-15-1153
Kvammen, O., Myklebust, T. A., Solberg, A., Moller, B., Klepp, O. H., Fossa, S. D., & Tandstad, T. (2019). Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953-2015: A population-based prospective cohort study. PLoS One, 14(12), e0225942. https://doi.org/10.1371/journal.pone.0225942
Langberg, M. K., Berglund-Nord, C., Cohn-Cedermark, G., Haugnes, H. S., Tandstad, T., & Langberg, C. W. (2018). Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA. Acta Oncol, 57(10), 1401-1406. https://doi.org/10.1080/0284186X.2018.1479072
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008). Low serum testosterone and mortality in older men. J Clin Endocrinol Metab, 93(1), 68-75. https://doi.org/10.1210/jc.2007-1792
Leibovitch, I., Baniel, J., Foster, R. S., & Donohue, J. P. (1995). The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. J Urol, 154(3), 935-939.
Leu, L., & Baribeault, D. (2010). A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract, 16(3), 167-171. https://doi.org/10.1177/1078155209346071
Lorch, A., Bascoul-Mollevi, C., Kramar, A., Einhorn, L., Necchi, A., Massard, C., . . . Beyer, J. (2011). Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol, 29(16), 2178-2184. https://doi.org/10.1200/JCO.2010.32.6678
Lorch, A., Beyer, J., Bascoul-Mollevi, C., Kramar, A., Einhorn, L. H., Necchi, A., . . . Kollmannsberger, C. K. (2010). Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol, 28(33), 4906-4911.
https://pubmed.ncbi.nlm.nih.gov/20956623/
10.1200/JCO.2009.26.8128
Lorch, A., Mollevi, A., Kramar, A., Einhorn, L. H., & Necchi, C. (2010). Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. J Clin Oncol, 28(15s), (suppl: abstr 4513).
Lotz, J. P., Bui, B., Gomez, F., Theodore, C., Caty, A., Fizazi, K., . . . Groupe d'Etudes des Tumeurs, U.-G. (2005). Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol, 16(3), 411-418. https://doi.org/10.1093/annonc/mdi087
Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). LOV-1999-07-02-63.
Luz, M. A., Kotb, A. F., Aldousari, S., Brimo, F., Tanguay, S., Kassouf, W., & Aprikian, A. G. (2010). Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol, 8, 97. https://doi.org/10.1186/1477-7819-8-97
Lyman, G. H., Bohlke, K., Falanga, A., & American Society of Clinical, O. (2015). Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract, 11(3), e442-444. https://doi.org/10.1200/JOP.2015.004473
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T. P., Valkonen, V. P., . . . Salonen, J. T. (2004). Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 27(5), 1036-1041. https://doi.org/10.2337/diacare.27.5.1036
MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., . . . Bankier, A. A. (2017). Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology, 284(1), 228-243. https://doi.org/10.1148/radiol.2017161659
Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E., & Ansell, S. M. (2005). Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol, 23(30), 7614-7620. https://doi.org/10.1200/JCO.2005.02.7243
Masterson, T. A., & Cary, C. (2018). The Use of Modified Templates in Early and Advanced Stage Nonseminomatous Germ Cell Tumor. Adv Urol, 2018, 6783147. https://doi.org/10.1155/2018/6783147
Masterson, T. A., Shayegan, B., Carver, B. S., Bajorin, D. F., Feldman, D. R., Motzer, R. J., . . . Sheinfeld, J. (2012). Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology, 79(1), 156-159. https://doi.org/10.1016/j.urology.2011.09.038
McCaffrey, J. A., Mazumdar, M., Bajorin, D. F., Bosl, G. J., Vlamis, V., & Motzer, R. J. (1997). Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol, 15(7), 2559-2563.
McKenney, J. K., Heerema-McKenney, A., & Rouse, R. V. (2007). Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Advances in anatomic pathology, 14(2), 69-92. https://doi.org/10.1097/PAP.0b013e31803240e6
Measurements, I. I. C. o. R. U. a. (1999). Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50). ICRU Report 62. Oxford University Press, Oxford, United Kingdom
Mezvrishvili, Z., & Managadze, L. (2006). Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma. Int Urol Nephrol, 38(3-4), 615-619. https://doi.org/10.1007/s11255-005-4793-x
Miller, J. C., & Einhorn, L. H. (1990). Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol, 17(1 Suppl 2), 36-39.
Mineur, P., De Cooman, S., Hustin, J., Verhoeven, G., & De Hertogh, R. (1987). Feminizing testicular Leydig cell tumor: hormonal profile before and after unilateral orchidectomy. J Clin Endocrinol Metab, 64(4), 686-691. https://doi.org/10.1210/jcem-64-4-686
Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016). The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 70(1), 93-105. https://doi.org/10.1016/j.eururo.2016.02.029
Moller, H., & Skakkebaek, N. E. (1999). Risk of testicular cancer in subfertile men: case-control study. BMJ, 318(7183), 559-562.
Mooney, K. L., & Kao, C. S. (2018). A Contemporary Review of Common Adult Non-germ Cell Tumors of the Testis and Paratestis. Surg Pathol Clin, 11(4), 739-758. https://doi.org/10.1016/j.path.2018.07.002
Mosharafa, A. A., Foster, R. S., Leibovich, B. C., Bihrle, R., Johnson, C., & Donohue, J. P. (2003). Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol, 169(6), 2126-2128. https://doi.org/10.1097/01.ju.0000060121.33899.4b
Motzer, R. J., Nichols, C. J., Margolin, K. A., Bacik, J., Richardson, P. G., Vogelzang, N. J., . . . Bosl, G. J. (2007). Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol, 25(3), 247-256. https://pubmed.ncbi.nlm.nih.gov/17235042/
10.1200/JCO.2005.05.4528
Murphy, B. R., Breeden, E. S., Donohue, J. P., Messemer, J., Walsh, W., Roth, B. J., & Einhorn, L. H. (1993). Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol, 11(2), 324-329. https://doi.org/10.1200/JCO.1993.11.2.324
Necchi, A., Lo Vullo, S., Giannatempo, P., Raggi, D., Calareso, G., Togliardi, E., . . . Salvioni, R. (2017). Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Ann Oncol, 28(6), 1346-1351. https://doi.org/10.1093/annonc/mdx124
Nichols, C. R. (1999). Treatment of recurrent germ cell tumors. Semin Surg Oncol, 17(4), 268-274. https://pubmed.ncbi.nlm.nih.gov/10588856/
Nichols, C. R., Roth, B., Albers, P., Einhorn, L. H., Foster, R., Daneshmand, S., . . . Kollmannsberger, C. (2013). Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol, 31(28), 3490-3493. https://doi.org/10.1200/JCO.2012.47.6010
Nicolai, N., Necchi, A., Gianni, L., Piva, L., Biasoni, D., Torelli, T., . . . Salvioni, R. (2009). Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int, 104(3), 340-346.
https://pubmed.ncbi.nlm.nih.gov/19239440/
10.1111/j.1464-410X.2009.08453.x
Nini, A., Konieczny, M., Winter, C., Lusch, A., Krauspe, R., & Albers, P. (2018). Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. Urol Oncol, 36(2), 82 e81-82 e85. https://doi.org/10.1016/j.urolonc.2017.10.016
Nonomura, N., Nagahara, A., Oka, D., Mukai, M., Nakai, Y., Nakayama, M., . . . Miki, T. (2009). Brain metastases from testicular germ cell tumors: a retrospective analysis. International journal of urology : official journal of the Japanese Urological Association, 16(11), 887-893. https://doi.org/10.1111/j.1442-2042.2009.02391.x
Nord, C., Bjoro, T., Ellingsen, D., Mykletun, A., Dahl, O., Klepp, O., . . . Fossa, S. D. (2003). Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol, 44(3), 322-328. https://doi.org/10.1016/s0302-2838(03)00263-x
Norway, C. R. o. (2019). Cancer in Norway 2018 - Cancer incidence, mortality, survival and prevalence in Norway.
Nuver, J., Smit, A. J., Sleijfer, D. T., van Gessel, A. I., van Roon, A. M., van der Meer, J., . . . Gietema, J. A. (2004). Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer, 40(5), 701-706. https://doi.org/10.1016/j.ejca.2003.12.012
Nuver, J., Smit, A. J., Wolffenbuttel, B. H., Sluiter, W. J., Hoekstra, H. J., Sleijfer, D. T., & Gietema, J. A. (2005). The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol, 23(16), 3718-3725.
https://pubmed.ncbi.nlm.nih.gov/15738540/
10.1200/JCO.2005.02.176
O'Sullivan, J. M., Huddart, R. A., Norman, A. R., Nicholls, J., Dearnaley, D. P., & Horwich, A. (2003). Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol, 14(1), 91-96.
Oechsle, K., & Bokemeyer, C. (2011). Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin North Am, 25(3), 605-613, ix. https://doi.org/10.1016/j.hoc.2011.03.012
Oechsle, K., Hartmann, M., Mehnert, A., Oing, C., Bokemeyer, C., & Vehling, S. (2016). Symptom burden in long-term germ cell tumor survivors. Support Care Cancer, 24(5), 2243-2250. https://doi.org/10.1007/s00520-015-3026-9
Oing, C., Giannatempo, P., Honecker, F., Oechsle, K., Bokemeyer, C., & Beyer, J. (2018). Palliative treatment of germ cell cancer. Cancer Treat Rev, 71, 102-107. https://doi.org/10.1016/j.ctrv.2018.10.007
Oing, C., Oechsle, K., Necchi, A., Loriot, Y., De Giorgi, U., Flechon, A., . . . Bokemeyer, C. (2014). Bone metastases in germ cell tumors: Results from an international data base. J Clin Oncol, (32), Supple; abstr 4559.
Oing, C., Oechsle, K., Necchi, A., Loriot, Y., De Giorgi, U., Flechon, A., . . . Bokemeyer, C. (2017). Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. Ann Oncol, 28(3), 576-582. https://doi.org/10.1093/annonc/mdw648
Oldenburg, J., Lorch, A., & Fossa, S. D. (2011). Late relapse of germ cell tumors. Hematol Oncol Clin North Am, 25(3), 615-626, x.
https://pubmed.ncbi.nlm.nih.gov/21570613/
10.1016/j.hoc.2011.03.006
Oldenburg, J., Wahlqvist, R., & Fossa, S. D. (2009). Late relapse of germ cell tumors. World Journal of Urology, 27(4), 493-500. https://doi.org/10.1007/s00345-009-0411-3
Oliver, R. T., Mason, M. D., Mead, G. M., von der Maase, H., Rustin, G. J., Joffe, J. K., . . . Stenning, S. P. (2005). Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet, 366(9482), 293-300.
https://pubmed.ncbi.nlm.nih.gov/16039331/
10.1016/S0140-6736(05)66984-X
Oliver, R. T., Mead, G. M., Rustin, G. J., Joffe, J. K., Aass, N., Coleman, R., . . . Stenning, S. P. (2011). Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214). J Clin Oncol, 29(8), 957-962.
https://pubmed.ncbi.nlm.nih.gov/21282539/
10.1200/JCO.2009.26.4655
Olofsson, S. E., Tandstad, T., Jerkeman, M., Dahl, O., Stahl, O., Klepp, O., . . . Cavallin-Stahl, E. (2011). Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol, 29(15), 2032-2039. https://doi.org/10.1200/JCO.2010.29.1278
Paffenholz, P., Grein, K., Heidegger, I., Nestler, T., Grabbert, M., Salem, J., . . . Heidenreich, A. (2019). Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World Journal of Urology, 37(9), 1907-1916. https://doi.org/10.1007/s00345-018-2598-7
Paffenholz, P., Pfister, D., & Heidenreich, A. (2020). Testis-preserving strategies in testicular germ cell tumors and germ cell neoplasia in situ. Transl Androl Urol, 9(Suppl 1), S24-S30. https://doi.org/10.21037/tau.2019.07.22
Patel, H. D., Singla, N., Ghandour, R. A., Freifeld, Y., Cheaib, J. G., Woldu, S. L., . . . Bagrodia, A. (2019). Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors. Cancer, 125(22), 3947-3952. https://doi.org/10.1002/cncr.32427
Pearce, S. M., Golan, S., Gorin, M. A., Luckenbaugh, A. N., Williams, S. B., Ward, J. F., . . . Eggener, S. E. (2017). Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol, 71(3), 476-482. https://doi.org/10.1016/j.eururo.2016.05.017
Pectasides, D., Pectasides, M., Farmakis, D., Aravantinos, G., Nikolaou, M., Koumpou, M., . . . Raptis, S. A. (2004). Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol, 46(2), 216-221. https://doi.org/10.1016/j.eururo.2004.03.001
S030228380400106X [pii]
Pectasides, D., Pectasides, M., Farmakis, D., Aravantinos, G., Nikolaou, M., Koumpou, M., . . . Skarlos, D. (2004). Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol, 15(3), 493-497.
Pettus, J. A., Carver, B. S., Masterson, T., Stasi, J., & Sheinfeld, J. (2009). Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology, 73(2), 328-331; discussion 331-322. https://doi.org/10.1016/j.urology.2008.08.501
Pico, J. L., Rosti, G., Kramar, A., Wandt, H., Koza, V., Salvioni, R., . . . Biron, P. (2005). A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol, 16(7), 1152-1159.
https://pubmed.ncbi.nlm.nih.gov/15928070/
10.1093/annonc/mdi228
Pierorazio, P. M., & Biles, M. J. (2019). Indications for Surgery in Disseminated Seminoma. Urol Clin North Am, 46(3), 399-407. https://doi.org/10.1016/j.ucl.2019.04.005
Pont, J., Albrecht, W., Postner, G., Sellner, F., Angel, K., & Holtl, W. (1996). Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol, 14(2), 441-448.
Puc, H. S., Heelan, R., Mazumdar, M., Herr, H., Scheinfeld, J., Vlamis, V., . . . Motzer, R. J. (1996). Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol, 14(2), 454-460.
Quek, M. L., Simma-Chiang, V., Stein, J. P., Pinski, J., Quinn, D. I., & Skinner, D. G. (2005). Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther, 5(5), 869-874. https://doi.org/10.1586/14737140.5.5.869
Raggi, D., Giannatempo, P., Miceli, R., Fare, E., Piva, L., Biasoni, D., . . . Necchi, A. (2017). Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. Am J Clin Oncol, 40(1), 60-65. https://doi.org/10.1097/COC.0000000000000113
Ravi, R., Ong, J., Oliver, R. T., Badenoch, D. F., Fowler, C. G., & Hendry, W. F. (1999). The management of residual masses after chemotherapy in metastatic seminoma. BJU Int, 83(6), 649-653.
Risk, M. C., & Foster, R. S. (2011). Postchemotherapy retroperitoneal lymph node dissection for testis cancer. Expert Rev Anticancer Ther, 11(1), 95-106. https://doi.org/10.1586/era.10.206
Roth, L. M., & Cheng, L. (2018). Classical gonadoblastoma: its relationship to the 'dissecting' variant and undifferentiated gonadal tissue. Histopathology, 72(4), 545-555. https://doi.org/10.1111/his.13387
Ruf, C. G., Sanatgar, N., Isbarn, H., Ruf, B., Simon, J., Fankhauser, C. D., & Dieckmann, K. P. (2020). Leydig-cell tumour of the testis: retrospective analysis of clinical and therapeutic features in 204 cases. World Journal of Urology. https://doi.org/10.1007/s00345-020-03079-1
Rutgers, J. L., Young, R. H., & Scully, R. E. (1988). The testicular "tumor" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol, 12(7), 503-513.
Sakaguchi, Y., & Isowa, N. (2012). Successful resection of mediastinal seminoma evaluated the response to induction chemotherapy with fluorodeoxyglucose-positron emission tomography. Ann Thorac Cardiovasc Surg, 18(1), 45-47. https://doi.org/10.5761/atcs.cr.11.01667
Sawrie, S. M., Guthrie, B. L., Spencer, S. A., Nordal, R. A., Meredith, R. F., Markert, J. M., . . . Fiveash, J. B. (2008). Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys, 70(1), 181-186. https://doi.org/10.1016/j.ijrobp.2007.05.084
Saxman, S. B., Nichols, C. R., & Einhorn, L. H. (1997). Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest, 111(3), 657-660. https://doi.org/10.1378/chest.111.3.657
Schirren, J., Trainer, S., Eberlein, M., Lorch, A., Beyer, J., & Bolukbas, S. (2012). The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. Thorac Cardiovasc Surg, 60(6), 405-412. https://doi.org/10.1055/s-0031-1299584
Schmoll, H. J. (2002). Extragonadal germ cell tumors. Ann Oncol, 13 Suppl 4, 265-272. https://doi.org/10.1093/annonc/mdf669
Schmoll, H. J., Kollmannsberger, C., Metzner, B., Hartmann, J. T., Schleucher, N., Schoffski, P., . . . German Testicular Cancer Study, G. (2003). Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol, 21(22), 4083-4091. https://doi.org/10.1200/JCO.2003.09.035
Schneider, D. T., Schuster, A. E., Fritsch, M. K., Hu, J., Olson, T., Lauer, S., . . . Perlman, E. J. (2001). Multipoint imprinting analysis indicates a common precursor cell for gonadal and nongonadal pediatric germ cell tumors. Cancer Res, 61(19), 7268-7276.
Scholz, M., Zehender, M., Thalmann, G. N., Borner, M., Thoni, H., & Studer, U. E. (2002). Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol, 13(1), 121-124. https://doi.org/10.1093/annonc/mdf003
Schultz, S. M., Einhorn, L. H., Conces, D. J., Jr., Williams, S. D., & Loehrer, P. J. (1989). Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol, 7(10), 1497-1503.
Sharmeen, F., Rosenthal, M. H., & Howard, S. A. (2014). The management of retroperitoneal lymphadenopathy in spermatocytic seminoma of the testicle. Clin Imaging, 38(2), 202-204. https://doi.org/10.1016/j.clinimag.2013.11.006
Sharp, D. S., Carver, B. S., Eggener, S. E., Kondagunta, G. V., Motzer, R. J., Bosl, G. J., & Sheinfeld, J. (2008). Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol, 26(34), 5524-5529.
https://pubmed.ncbi.nlm.nih.gov/18936477/
10.1200/JCO.2007.15.7453
Shores, M. M., Matsumoto, A. M., Sloan, K. L., & Kivlahan, D. R. (2006). Low serum testosterone and mortality in male veterans. Arch Intern Med, 166(15), 1660-1665. https://doi.org/10.1001/archinte.166.15.1660
Simone, C. B., 2nd, Kramer, K., O'Meara, W. P., Bekelman, J. E., Belard, A., McDonough, J., & O'Connell, J. (2012). Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys, 82(1), 242-249. https://doi.org/10.1016/j.ijrobp.2010.11.021
Skoogh, J., Steineck, G., Cavallin-Stahl, E., Wilderang, U., Hakansson, U. K., Johansson, B., . . . Swenoteca. (2011). Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. International Journal of Andrology, 34(2), 183-192.
https://doi.org/10.1111/J.1365-2605.2010.01073.X
Sleijfer, S. (2001). Bleomycin-induced pneumonitis. Chest, 120(2), 617-624.
Smith, E. M., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., . . . Alliance for Clinical Trials in, O. (2013). Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA, 309(13), 1359-1367. https://doi.org/10.1001/jama.2013.2813
Socialstyrelsen. (2019). Cancer Incidence in Sweden 2018.
Sohaib, S. A., Koh, D. M., Barbachano, Y., Parikh, J., Husband, J. E., Dearnaley, D. P., . . . Huddart, R. (2009). Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol, 64(4), 362-367. https://doi.org/10.1016/j.crad.2008.10.011
Spermon, J. R., De Geus-Oei, L. F., Kiemeney, L. A., Witjes, J. A., & Oyen, W. J. (2002). The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int, 89(6), 549-556.
Spiess, P. E., Brown, G. A., Liu, P., Tannir, N. M., Tu, S. M., Evans, J. G., . . . Pisters, L. L. (2006). Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer, 107(7), 1483-1490. https://doi.org/10.1002/cncr.22182
Sprauten, M., Haugnes, H. S., Brydoy, M., Kiserud, C., Tandstad, T., Bjoro, T., . . . Oldenburg, J. (2015). Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Ann Oncol, 26(10), 2133-2140. https://doi.org/10.1093/annonc/mdv328
Srikanthan, A., Tran, B., Beausoleil, M., Jewett, M. A., Hamilton, R. J., Sturgeon, J. F., . . . Bedard, P. L. (2015). Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol, 33(6), 582-587. https://doi.org/10.1200/JCO.2014.58.6537
Stang, A., Trabert, B., Wentzensen, N., Cook, M. B., Rusner, C., Oosterhuis, J. W., & McGlynn, K. A. (2012). Gonadal and extragonadal germ cell tumours in the United States, 1973-2007. Int J Androl, 35(4), 616-625. https://doi.org/10.1111/j.1365-2605.2011.01245.x
Steiner, H., Holtl, L., Wirtenberger, W., Berger, A. P., Bartsch, G., & Hobisch, A. (2002). Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology, 60(2), 324-328.
Steiner, H., Scheiber, K., Berger, A. P., Rein, P., Hobisch, A., Aufderklamm, J., . . . Zangerl, F. (2011). Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int, 107(7), 1074-1079. https://doi.org/10.1111/j.1464-410X.2010.09658.x
Stepanian, S., Patel, M., & Porter, J. (2016). Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique. Eur Urol, 70(4), 661-667. https://doi.org/10.1016/j.eururo.2016.03.031
Stephenson, A. J., Bosl, G. J., Motzer, R. J., Bajorin, D. F., Stasi, J. P., & Sheinfeld, J. (2007). Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol, 25(35), 5597-5602. https://doi.org/10.1200/JCO.2007.12.0808
Sturgeon, J. F., Moore, M. J., Kakiashvili, D. M., Duran, I., Anson-Cartwright, L. C., Berthold, D. R., . . . Jewett, M. A. (2010). Non-Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital's Experience. Eur Urol.
https://pubmed.ncbi.nlm.nih.gov/21190791/
10.1016/j.eururo.2010.12.010
Svartberg, J., von Muhlen, D., Schirmer, H., Barrett-Connor, E., Sundfjord, J., & Jorde, R. (2004). Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol, 150(1), 65-71. https://doi.org/10.1530/eje.0.1500065
Tandstad, T., Cavallin-Stahl, E., Dahl, O., Haugnes, H. S., Langberg, C., Laurell, A., . . . Cohn-Cedermark, G. (2014). Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA. J Clin Oncol, 32(5s), suppl; abstract 4508.
Tandstad, T., Dahl, O., Cohn-Cedermark, G., Cavallin-Stahl, E., Stierner, U., Solberg, A., . . . Klepp, O. (2009). Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol, 27(13), 2122-2128.
https://pubmed.ncbi.nlm.nih.gov/19307506/
10.1200/JCO.2008.18.8953
Tandstad, T., Smaaland, R., Solberg, A., Bremnes, R. M., Langberg, C. W., Laurell, A., . . . Cohn-Cedermark, G. (2011). Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol, 29(6), 719-725.
https://pubmed.ncbi.nlm.nih.gov/21205748/
10.1200/JCO.2010.30.1044
Tandstad, T., Stahl, O., Dahl, O., Haugnes, H. S., Hakansson, U., Karlsdottir, A., . . . Swenoteca. (2016). Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy, a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. https://doi.org/10.1093/annonc/mdw164
Tandstad, T., Stahl, O., Hakansson, U., Dahl, O., Haugnes, H. S., Klepp, O. H., . . . Swenoteca. (2014). One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol, 25(11), 2167-2172. https://doi.org/10.1093/annonc/mdu375
Thompson, R. H., Carver, B. S., Bosl, G. J., Bajorin, D., Motzer, R., Feldman, D., . . . Sheinfeld, J. (2010). Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer, 116(22), 5243-5250. https://doi.org/10.1002/cncr.25266
Thorsen, L., Haugnes HS, Fosså SD, Brydoy M, Tandstad T, Wisløff T, Gjerset GM, Edvardsen E, Larsen K, Sandset PM, Henriksson CA, Raastad T, Negaard H. (2020). Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature. Int J Cancer, In press.
Tookman, L., Rashid, S., Matakidou, A., Phillips, M., Wilson, P., Ansell, W., . . . Shamash, J. (2013). Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma. Acta Oncol, 52(5), 987-993. https://doi.org/10.3109/0284186X.2012.714078
Trama, A., Mallone, S., Nicolai, N., Necchi, A., Schaapveld, M., Gietema, J., . . . Group, R. W. (2012). Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. Eur J Cancer, 48(2), 159-169. https://doi.org/10.1016/j.ejca.2011.08.020
Tryakin, A., Fedyanin, M., Kanagavel, D., Fainstein, I., Sergeev, J., Polockij, B., . . . Tjulandin, S. (2011). Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study. Urology, 78(3), 620-625. https://doi.org/10.1016/j.urology.2011.05.005
Ueno, T., Tanaka, Y. O., Nagata, M., Tsunoda, H., Anno, I., Ishikawa, S., . . . Itai, Y. (2004). Spectrum of germ cell tumors: from head to toe. Radiographics, 24(2), 387-404. https://doi.org/10.1148/rg.242035082
Utz, D. C., & Buscemi, M. F. (1971). Extragonadal testicular tumors. J Urol, 105(2), 271-274. https://doi.org/10.1016/s0022-5347(17)61508-8
van den Belt-Dusebout, A. W., Nuver, J., de Wit, R., Gietema, J. A., ten Bokkel Huinink, W. W., Rodrigus, P. T., . . . van Leeuwen, F. E. (2006). Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol, 24(3), 467-475.
https://ascopubs.org/doi/10.1200/JCO.2005.02.7193?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
10.1200/JCO.2005.02.7193
van Dijk, M. R., Steyerberg, E. W., & Habbema, J. D. (2006). Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer, 42(7), 820-826.
https://pubmed.ncbi.nlm.nih.gov/16574403/
10.1016/j.ejca.2005.08.043
Vaughn, D. J., Hwang, W. T., Lal, P., Rosen, M. A., Gallagher, M., & O'Dwyer, P. J. (2015). Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer, 121(9), 1463-1468. https://doi.org/10.1002/cncr.29213
Vuky, J., Bains, M., Bacik, J., Higgins, G., Bajorin, D. F., Mazumdar, M., . . . Motzer, R. J. (2001). Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol, 19(3), 682-688. https://doi.org/10.1200/JCO.2001.19.3.682
Warde, P., Specht, L., Horwich, A., Oliver, T., Panzarella, T., Gospodarowicz, M., & von der Maase, H. (2002). Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol, 20(22), 4448-4452.
Weibring, K., Nord, C., Stahl, O., Eberhard, J., Sandberg, K., Johansson, H., . . . Cohn-Cedermark, G. (2019). Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment. Ann Oncol, 30(4), 604-611. https://doi.org/10.1093/annonc/mdz017
Weijl, N. I., Rutten, M. F., Zwinderman, A. H., Keizer, H. J., Nooy, M. A., Rosendaal, F. R., . . . Osanto, S. (2000). Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol, 18(10), 2169-2178. https://doi.org/10.1200/JCO.2000.18.10.2169
Weissbach, L., Bussar-Maatz, R., & Mann, K. (1997). The value of tumor markers in testicular seminomas. Results of a prospective multicenter study. Eur Urol, 32(1), 16-22.
Wethal, T., Kjekshus, J., Roislien, J., Ueland, T., Andreassen, A. K., Wergeland, R., . . . Fossa, S. D. (2007). Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv, 1(1), 8-16. https://doi.org/10.1007/s11764-007-0012-3
Widen, S. E., & Erlandsson, S. I. (2004). Self-reported tinnitus and noise sensitivity among adolescents in Sweden. Noise Health, 7(25), 29-40.
Wierecky, J., Kollmannsberger, C., Boehlke, I., Kuczyk, M., Schleicher, J., Schleucher, N., . . . Bokemeyer, C. (2005). Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol, 131(4), 255-260. https://doi.org/10.1007/s00432-004-0628-x
Wilder, R. B., Buyyounouski, M. K., Efstathiou, J. A., & Beard, C. J. (2012). Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys, 83(4), e445-452. https://doi.org/10.1016/j.ijrobp.2012.01.044
Zagars, G. K., Ballo, M. T., Lee, A. K., & Strom, S. S. (2004). Mortality after cure of testicular seminoma. J Clin Oncol, 22(4), 640-647. https://doi.org/10.1200/JCO.2004.05.205
JCO.2004.05.205 [pii]
Zhang, M., Kao, C. S., Ulbright, T. M., & Epstein, J. I. (2013). Testicular fibrothecoma: a morphologic and immunohistochemical study of 16 cases. Am J Surg Pathol, 37(8), 1208-1214. https://doi.org/10.1097/PAS.0b013e318286c129
Zhou, E. S., Hall, K. T., Michaud, A. L., Blackmon, J. E., Partridge, A. H., & Recklitis, C. J. (2019). Open-label placebo reduces fatigue in cancer survivors: a randomized trial. Support Care Cancer, 27(6), 2179-2187. https://doi.org/10.1007/s00520-018-4477-6
Zilli, T., Boudreau, C., Doucet, R., Alizadeh, M., Lambert, C., van Nguyen, T., & Taussky, D. (2011). Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma. Acta Oncol, 50(4), 555-562. https://doi.org/10.3109/0284186x.2011.564650